Registration Dossier

Administrative data

Description of key information

Key value for chemical safety assessment

Skin sensitisation

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed (not sensitising)
Additional information:

Key study

In a fully reliable study in vivo: LLNA (Bernard 2012) was concluded that methyl benzoate does not show a skin sensitisation potential.

Supporting information

In an open epicutaneous test in vivo (Kecak 1985) it was shown that methyl benzoate has no skin sensitising potential.


Migrated from Short description of key information:
The test item methyl benzoate does not show an allergic potential to the skin.

Justification for selection of skin sensitisation endpoint:
GLP study according to OECD TG 429 (Skin sensitisation: Local Lymph Node Assay).

Respiratory sensitisation

Endpoint conclusion
Endpoint conclusion:
no study available
Additional information:
Migrated from Short description of key information:
not required

Justification for classification or non-classification

- skin sensitisation:

Based on the above stated assessment of the skin sensitisation potential, methyl benzoate does not need to be classified according to Council Directive 2001/59/EC (28th ATP of Directive 67/548/EEC) or according to CLP (Regulation (EC) No 1272/2008 of the European Parliament and of the Council) as implementation of UN-GHS in the EU.